NCT00410423View on ClinicalTrials.gov

Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

May 31, 2013

Study Completion Date

September 30, 2014

Conditions
Relapsed Acute LeukemiaRefractory Acute Leukemia
Interventions
DRUG

Bortezomib with mitoxantrone, etoposide and cytarabine

All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.

DRUG

Bortezomib 1.0mg/m^2

All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.

DRUG

Bortezomib 1.3mg/m^2

All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER